ES2153671T3 - Peptidos neuroactivos. - Google Patents

Peptidos neuroactivos.

Info

Publication number
ES2153671T3
ES2153671T3 ES97927691T ES97927691T ES2153671T3 ES 2153671 T3 ES2153671 T3 ES 2153671T3 ES 97927691 T ES97927691 T ES 97927691T ES 97927691 T ES97927691 T ES 97927691T ES 2153671 T3 ES2153671 T3 ES 2153671T3
Authority
ES
Spain
Prior art keywords
neuroactive peptides
specific identification
neuroactive
peptides
nmda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97927691T
Other languages
English (en)
Inventor
Joseph R Moskal
Hirotaka Yamamoto
Patricia A Colley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NYXIS Neuro Therapies Inc
Original Assignee
NYXIS Neuro Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NYXIS Neuro Therapies Inc filed Critical NYXIS Neuro Therapies Inc
Application granted granted Critical
Publication of ES2153671T3 publication Critical patent/ES2153671T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES Y PROCEDIMIENTOS PARA LA IDENTIFICACION ESPECIFICA DE RECEPTORES DE NMDA, ASI COMO PARA LA IDENTIFICACION ESPECIFICA Y MANIPULACION DE LA ACTIVIDAD BIOLOGICA CO - AGONISTA DE LA GLICINA DEL NMDA.
ES97927691T 1996-05-17 1997-05-16 Peptidos neuroactivos. Expired - Lifetime ES2153671T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/649,272 US5763393A (en) 1996-05-17 1996-05-17 Neuroactive peptides

Publications (1)

Publication Number Publication Date
ES2153671T3 true ES2153671T3 (es) 2001-03-01

Family

ID=24604116

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97927691T Expired - Lifetime ES2153671T3 (es) 1996-05-17 1997-05-16 Peptidos neuroactivos.

Country Status (12)

Country Link
US (2) US5763393A (es)
EP (2) EP1077217A3 (es)
JP (1) JP2000501746A (es)
AT (1) ATE197307T1 (es)
AU (1) AU3209097A (es)
CA (1) CA2255659C (es)
DE (1) DE69703449T2 (es)
DK (1) DK0914331T3 (es)
ES (1) ES2153671T3 (es)
GR (1) GR3035227T3 (es)
PT (1) PT914331E (es)
WO (1) WO1997043306A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1296999A2 (en) * 2000-06-22 2003-04-02 NYXIS NeuroTherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
US20030022253A1 (en) * 2001-07-25 2003-01-30 Nyxis Neurotherapies, Inc. Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP2485751B1 (en) 2009-10-05 2014-05-21 Northwestern University GLYX-13 for use in a method of treating refractory depression
SG10201501050RA (en) 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
MX357761B (es) 2011-04-27 2018-07-23 Univ Northwestern Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
US8798716B1 (en) 2011-11-03 2014-08-05 Solstice Corporation Fiducial markers and related methods
US8974365B2 (en) 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
CA3216579A1 (en) 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
JP6419087B2 (ja) 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201505937SA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
GB201319437D0 (en) * 2013-11-04 2013-12-18 Nanomerics Ltd Delivery of drugs
AU2015249222A1 (en) 2014-04-25 2016-11-17 Naurex, Inc. Stable compositions of neuroactive peptides
JP2017525684A (ja) * 2014-07-24 2017-09-07 ノーレックス インコーポレイテッド Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法
KR20170040351A (ko) 2014-08-14 2017-04-12 노렉스, 인크. Nmda 조절인자를 사용하여 우울증을 치료하는 방법
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109890825B (zh) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
JP2019527235A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3706734A1 (en) 2017-11-10 2020-09-16 Naurex Inc. Methods of administration of nmda receptor agonists
US20200368310A1 (en) 2017-12-05 2020-11-26 Naurex, INC Treatment with nmda receptor modulators
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列

Also Published As

Publication number Publication date
CA2255659A1 (en) 1997-11-20
CA2255659C (en) 2005-03-15
EP1077217A2 (en) 2001-02-21
DE69703449T2 (de) 2001-06-07
EP1077217A3 (en) 2004-01-02
AU3209097A (en) 1997-12-05
DE69703449D1 (de) 2000-12-07
DK0914331T3 (da) 2001-02-12
GR3035227T3 (en) 2001-04-30
JP2000501746A (ja) 2000-02-15
EP0914331A1 (en) 1999-05-12
EP0914331B1 (en) 2000-11-02
US6107271A (en) 2000-08-22
ATE197307T1 (de) 2000-11-15
PT914331E (pt) 2001-04-30
WO1997043306A1 (en) 1997-11-20
US5763393A (en) 1998-06-09

Similar Documents

Publication Publication Date Title
DK0914331T3 (da) Neuroaktive peptider
DE59710609D1 (de) Mittel zur Herstellung von Leder
CY1114164T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
ITTO950367A0 (it) Proteine di prrsv ricombinanti, corredi diagnostici e vaccini contenenti tali proteine di prrsv ricombinanti.
DE69739245D1 (de) System zur Identifizierung von Material mittels NIR-Spektrometrie
BR0009206A (pt) Isolamento e análise de proteina
FI963461A0 (fi) Häiriönpoistoaineet immunologisia määrityksiä varten
DE69739219D1 (de) Peptide und zusammensetzungen, die an den thrombopoietin-rezeptor binden
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
DE69737948D1 (de) Vorrichtung zur rekonstruktion von sehnen
EP0918787A4 (en) COMPOSITIONS AND METHODS FOR ANTISENSE INHIBITION OF PROTEIN TRANSLATION
NO984644D0 (no) Ikke-dendrittisk ryggradpeptidbµrer
ATE242264T1 (de) Heptapeptid oxytocin analogen
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
DE59711900D1 (de) Vorrichtung zur kuppelprojektion
GB9816514D0 (en) Novel method
ATE412747T1 (de) Neues tumor-antigen-protein sart-3 und tumor- antigen-peptid davon
EP0749320A4 (en) FIBRIN-SPECIFIC ANTIBODIES FOR USE AS ANTITHROMBOSE AGENT
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
DE59711564D1 (de) Wiederlösbare, selbstklebende Vorrichtung
DE69938130D1 (de) Neue peptide
AU2172597A (en) Protein phosphatase-1 catalytic subunit interactions
TR199701666A3 (tr) Sismanliga karsi proteinler
EP1032411A4 (en) HYPUSINE REAGENT FOR THE SYNTHESIS OF PEPTIDES

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 914331

Country of ref document: ES